Advertisement


Andrew J. Armstrong, MD, MS, on ARCHES: 5-Year Overall Survival Follow-up

2025 ASCO Annual Meeting

Advertisement

Andrew J. Armstrong, MD, MS, of Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, discusses the 5-year overall survival analysis of the ARCHES trial, which investigated enzalutamide plus androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer (Abstract 5005). 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
So in 2025, the standard of care for men who have metastatic hormone-sensitive prostate cancer is treatment intensification, either with doublet therapy, that means androgen deprivation therapy plus an androgen receptor pathway inhibitor, or triplet therapy with that doublet plus docetaxel. And that's based on data like the ARCHES trial that I'm presenting at ASCO 2025. In 2019, we published in the Journal of Clinical Oncology that enzalutamide plus ADT in the ARCHES trial delayed progression-free survival by over 60%. That led to the FDA approval of the enzalutamide ADT regimen based on the ARCHES trial of over 1,150 patients. This is a randomized global trial, the primary endpoint of which was radiographic progression-free survival. In 2021 we updated the data that shows that that delay in progression-free survival translated into an overall survival improvement by about 30%. So this was a remarkable finding in 2021. In 2025 we're updating the data where the minimum follow-up for all patients is now five years. So we're asking the question what does this long-term survival look like for our patients and this is applicable to clinical practice as we're now treating patients, as I mentioned, in 2025 with treatment intensification routinely. And the question is what happens to these men long-term. The great news from the ARCHES long-term survival follow-up is that men are living longer, a 30% extension of survival. That means at five years 13% more men are alive at that important landmark. This ranges across different subgroups by disease volume, disease risk, geography, age, prior chemotherapy, but the absolute improvement ranges from about 9 to 17%. One of the more remarkable findings was the median survival improvement in high-volume disease patients. Survival improved from four years to about seven years. That's three extra years of life where these men can enjoy time with their family, delay progression and the symptomatology that that causes, delay the need for chemotherapy and subsequent therapy, which have additional toxicities. Now with this improved efficacy and delaying progression and living longer comes the need for close attention to survivorship. There are enhanced toxicities with all of the androgen receptor pathway inhibitors. With enzalutamide we do see increases in fatigue, falls, some fractures, particularly in older men. We see neurocognitive effects in a few percent of patients. Radioligand therapy, EZH2 inhibitors, you know, ways to further build on this and extend the lives of our patients.

Related Videos

Prostate Cancer

Nicholas D. James, PhD, FRCP, MBBS, on Using AI to Identify Benefit From Prostate Cancer Therapy

Nicholas D. James, PhD, FRCP, MBBS, of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, describes the use of a multimodal artificial intelligence (AI) model to identify benefit from second-generation androgen receptor pathway inhibitors in patients with high-risk nonmetastatic prostate cancer participating in the STAMPEDE trial (Abstract 5001). 

 

Asaf Maoz, MD, on Li-Fraumeni Syndrome: Multimodality Screening Program 

Asaf Maoz, MD, of Dana-Farber Cancer Institute/Mass General Brigham/Harvard Medical School, reviews the results of a prospective study of whole-body magnetic resonance imaging as part of cancer screening for individuals with Li-Fraumeni syndrome (Abstract 10501). 

Lung Cancer

Martin Reck, MD, PhD, on Postsurgical MRD, Genomic Mutations, and Outcomes in Resectable NSCLC: AEGEAN Trial

Martin Reck, MD, PhD, of LungenClinic Grosshansdorf, Germany, discusses data from the phase III AEGEAN trial that studied perioperative durvalumab and neoadjuvant chemotherapy. Patients who were MRD-positive after surgery had significantly worse disease-free survival compared to MRD-negative patients. In addition, mutations in KEAP1 and KMT2C were associated with MRD positivity and reduced benefit from the regimen, identifying a small high-risk subgroup with poor prognosis (Abstract 8009). 

Pancreatic Cancer

Sameek Roychowdhury, MD, PhD, on Telemedicine in Clinical Trials

Sameek Roychowdhury, MD, PhD, of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University Wexner Medical Center, discusses a recently opened telemedicine clinical trial of pemigatinib in patients with advanced or metastatic FGFR-mutated pancreatic cancer, and the germination of a new initiative, TNT Cancer, which focuses on leveraging telemedicine to bring trials nationwide.

Prostate Cancer

Praful Ravi, MBBChir, MRCP, on High-Risk Localized Prostate Cancer: Docetaxel With ADT and Radiotherapy

Praful Ravi, MBBChir, MRCP, of Dana-Farber Cancer Institute, presents findings from an ICECaP individual patient-data meta-analysis of randomized controlled trials on a treatment strategy used in high-risk localized prostate cancer (Abstract 5013). 

Advertisement

Advertisement




Advertisement